BioSpace News Archive

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, May 5, 2022.

SeaSpine Holdings Corporation announced the full commercial launch of OsteoTorrent and OsteoTorrent C, both of which are new Accell DBM Putties packaged and sterilized in a dry state and designed to further improve osteoinductive potential and shelf-life, while allowing surgeons to reconstitute with saline, blood or bone marrow aspirate.

Semler Scientific, Inc. reported financial results for the three months ended March 31, 2022.

Karyopharm Therapeutics Inc. announced that in connection with the hiring of Reshma Rangwala, Executive Vice President, Chief Medical Officer, the Compensation Committee of Karyopharm’s Board of Directors granted a stock option to purchase 100,000 shares of Karyopharm’s common stock and 65,000 restricted stock units to Dr. Rangwala, with a grant date of April 29, 2022.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 100,000 shares of the company’s common stock to two new employees.

Terves today announced that it has obtained a significant patent infringement, validity and lost profits judgment of over $700,000 against competitor Ecometal, Inc. and Nick Yuan over Terves’ patented TervAlloy dissolvable metal used by the fracking industry.

The vital signs monitoring systems market is expected to witness strong growth over the forecast period.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter financial results on Thursday, May 5, 2022.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a virtual meeting of the U.S. Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee to review the resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) has been scheduled for June 17, 2022.

Selecta Biosciences, Inc. announced six upcoming presentations, including three joint presentations with our partner AskBio, at the 25th Annual Meeting of the American Society of Gene & Cell Therapy, to be held virtually and in-person from May 16-19, 2022 in Washington, D.C.